MX351453B - Composiciones de liberacion sostenida a base de lipidos anfipaticos. - Google Patents
Composiciones de liberacion sostenida a base de lipidos anfipaticos.Info
- Publication number
- MX351453B MX351453B MX2014006271A MX2014006271A MX351453B MX 351453 B MX351453 B MX 351453B MX 2014006271 A MX2014006271 A MX 2014006271A MX 2014006271 A MX2014006271 A MX 2014006271A MX 351453 B MX351453 B MX 351453B
- Authority
- MX
- Mexico
- Prior art keywords
- sustained release
- release compositions
- amphipathic lipid
- based sustained
- amphipathic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000013268 sustained release Methods 0.000 title abstract 3
- 239000012730 sustained-release form Substances 0.000 title abstract 3
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161566279P | 2011-12-02 | 2011-12-02 | |
| PCT/US2012/067361 WO2013082470A1 (en) | 2011-12-02 | 2012-11-30 | Amphipathic lipid-based sustained release compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014006271A MX2014006271A (es) | 2014-09-22 |
| MX351453B true MX351453B (es) | 2017-10-16 |
Family
ID=48524178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014006271A MX351453B (es) | 2011-12-02 | 2012-11-30 | Composiciones de liberacion sostenida a base de lipidos anfipaticos. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9248096B2 (enExample) |
| EP (1) | EP2785333A4 (enExample) |
| JP (1) | JP2015500241A (enExample) |
| AU (1) | AU2012345726B2 (enExample) |
| BR (1) | BR112014013175B1 (enExample) |
| CA (1) | CA2854054C (enExample) |
| MX (1) | MX351453B (enExample) |
| WO (1) | WO2013082470A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| CA2923029A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| US20170071859A1 (en) * | 2015-09-16 | 2017-03-16 | Corr-Jensen, Inc. | Multi-phase release of sports nutrition and energy drink compositions utilizing lipid particulates |
| HRP20220156T1 (hr) | 2015-09-17 | 2022-04-15 | Modernatx, Inc. | Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava |
| DK3386484T3 (da) | 2015-12-10 | 2022-07-04 | Modernatx Inc | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler |
| RS63051B1 (sr) | 2015-12-22 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularnu isporuku agenasa |
| EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
| RS63953B1 (sr) | 2017-03-15 | 2023-02-28 | Modernatx Inc | Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava |
| EP3638678B1 (en) | 2017-06-14 | 2025-12-03 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
| US20190110988A1 (en) * | 2017-10-17 | 2019-04-18 | Lemulsa Technologies Inc. | Delivery System That Utilizes Liposomal or Emulsion Vehicles |
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| CN112996854B (zh) | 2018-09-19 | 2024-08-30 | 摩登纳特斯有限公司 | 高纯度peg脂质和其用途 |
| PL3886814T3 (pl) | 2018-11-26 | 2025-04-07 | The Procter & Gamble Company | Stały preparat farmaceutyczny zawierający kwas liponowy i jego zastosowanie |
| AU2020351220A1 (en) | 2019-09-19 | 2022-04-07 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| EP4031524A1 (en) | 2019-09-19 | 2022-07-27 | ModernaTX, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6348226A (ja) * | 1986-08-14 | 1988-02-29 | Ono Pharmaceut Co Ltd | 徐放性を有する経口投与用固形製剤 |
| US5993850A (en) | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
| US6077534A (en) * | 1997-09-02 | 2000-06-20 | Klinge Pharma Gmbh | Production of pharmaceutical formulations for treatment of edema and venous disorders |
| DE19740983A1 (de) * | 1997-09-18 | 1999-04-08 | Warner Lambert Co N D Ges D St | Verfahren zur Erschwerung der Extraktion von Wirkstoffen aus Tabletten |
| WO1999048372A1 (en) | 1998-03-23 | 1999-09-30 | General Mills, Inc. | Encapsulation of components into edible products |
| WO2000076478A1 (en) * | 1999-06-14 | 2000-12-21 | Cosmo S.P.A. | Controlled release and taste masking oral pharmaceutical compositions |
| US7314640B2 (en) * | 2003-07-11 | 2008-01-01 | Mongkol Sriwongjanya | Formulation and process for drug loaded cores |
| PL204079B1 (pl) * | 2004-08-12 | 2009-12-31 | Inst Farmaceutyczny | Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania |
| CA2678367C (en) | 2007-03-02 | 2014-07-08 | Farnam Companies, Inc. | Sustained release compositions using wax-like materials |
| US8404275B2 (en) * | 2007-07-01 | 2013-03-26 | Vitalis Llc | Combination tablet with chewable outer layer |
| AU2009289464B2 (en) * | 2008-09-04 | 2015-12-10 | Farnam Companies, Inc. | Chewable sustained release formulations |
| WO2010136193A1 (en) * | 2009-05-28 | 2010-12-02 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical composition comprising tamsulosin |
-
2012
- 2012-11-30 CA CA2854054A patent/CA2854054C/en active Active
- 2012-11-30 MX MX2014006271A patent/MX351453B/es active IP Right Grant
- 2012-11-30 AU AU2012345726A patent/AU2012345726B2/en active Active
- 2012-11-30 US US13/690,974 patent/US9248096B2/en active Active
- 2012-11-30 BR BR112014013175-9A patent/BR112014013175B1/pt active IP Right Grant
- 2012-11-30 WO PCT/US2012/067361 patent/WO2013082470A1/en not_active Ceased
- 2012-11-30 JP JP2014544937A patent/JP2015500241A/ja active Pending
- 2012-11-30 EP EP12854388.1A patent/EP2785333A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2854054A1 (en) | 2013-06-06 |
| MX2014006271A (es) | 2014-09-22 |
| AU2012345726A1 (en) | 2014-05-29 |
| EP2785333A4 (en) | 2015-04-01 |
| CA2854054C (en) | 2020-05-12 |
| EP2785333A1 (en) | 2014-10-08 |
| AU2012345726B2 (en) | 2017-04-13 |
| NZ624641A (en) | 2016-04-29 |
| BR112014013175A8 (pt) | 2021-06-08 |
| WO2013082470A1 (en) | 2013-06-06 |
| BR112014013175B1 (pt) | 2022-08-09 |
| US9248096B2 (en) | 2016-02-02 |
| JP2015500241A (ja) | 2015-01-05 |
| BR112014013175A2 (pt) | 2017-06-13 |
| US20130142876A1 (en) | 2013-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014013175A2 (pt) | composições de liberação prolongada baseadas em lipídios anfipáticos | |
| ES3065854T3 (en) | Biodegradable lipids for the delivery of active agents | |
| AR081681A1 (es) | METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA | |
| AU2014359194A1 (en) | Lipid microcapsules preferably comprising a retinoid, and composition containing same, method for the production thereof, and use thereof in dermatology | |
| SG11201406141UA (en) | Immortalized stem cells and medicinal composition and medicinal preparation comprising product thereof as active ingredient | |
| PT3083556T (pt) | Lípidos e composições lipídicas para a entrega de agentes ativos | |
| EP2779996C0 (en) | DRUG DELIVERY SYSTEM PROVIDING PROLONGED DELIVERY OF BIOACTIVE AGENTS | |
| WO2013177419A3 (en) | Lipid nanoparticle compositions and methods of making and methods of using the same | |
| PT3061454T (pt) | Composições veterinárias orais parasiticidas compreendendo agentes activos de actuação sistémica, métodos e as suas utilizações | |
| IN2015DN03984A (enExample) | ||
| EA201291211A1 (ru) | Фармацевтические композиции, содержащие гидроморфон и налоксон | |
| GB201502755D0 (en) | Supported catalyst and active form thereof, and preparation method and use | |
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| IL236466B (en) | Pharmaceutical composition for the release of active components | |
| EP2611847A4 (de) | Amphiphil zur solubilisierung schwerlöslicher wirkstoffe | |
| PT2846839T (pt) | Formulações para a administração de ingredientes ativos | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| HUE050945T2 (hu) | Gyógyszerforma hatóanyagok nyújtott felszabadítására | |
| ZA201306239B (en) | Storage-stable formulation of paracetamol in aqueous solution | |
| IN2015DN04074A (enExample) | ||
| MX367773B (es) | Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos. | |
| GB201114230D0 (en) | Addition copolymers and their use | |
| WO2011093831A3 (en) | Effervescent formulations comprising cefprozil as active agent | |
| WO2013115736A3 (en) | Bilayer tablet formulations of flurbiprofen and glucosamin | |
| PL2704698T3 (pl) | Postać leku do kontrolowanego uwalniania substancji czynnych |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |